WO1997008205B1 - Anticorps presentant deux specificites ou plus pour l'elimination specifique de cellules in vivo - Google Patents
Anticorps presentant deux specificites ou plus pour l'elimination specifique de cellules in vivoInfo
- Publication number
- WO1997008205B1 WO1997008205B1 PCT/EP1996/003734 EP9603734W WO9708205B1 WO 1997008205 B1 WO1997008205 B1 WO 1997008205B1 EP 9603734 W EP9603734 W EP 9603734W WO 9708205 B1 WO9708205 B1 WO 9708205B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- antigen
- tumor
- antigens
- cell
- Prior art date
Links
- 102000004965 antibodies Human genes 0.000 title claims abstract 24
- 108090001123 antibodies Proteins 0.000 title claims abstract 24
- 238000003379 elimination reaction Methods 0.000 title 1
- 108091007172 antigens Proteins 0.000 claims abstract 28
- 102000038129 antigens Human genes 0.000 claims abstract 28
- 239000000427 antigen Substances 0.000 claims abstract 27
- 239000003814 drug Substances 0.000 claims abstract 4
- 239000000203 mixture Substances 0.000 claims abstract 3
- 210000004881 tumor cells Anatomy 0.000 claims 7
- 210000004027 cells Anatomy 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 102000005614 monoclonal antibodies Human genes 0.000 claims 5
- 108010045030 monoclonal antibodies Proteins 0.000 claims 5
- 206010024324 Leukaemias Diseases 0.000 claims 2
- 238000009169 immunotherapy Methods 0.000 claims 2
- 230000003211 malignant Effects 0.000 claims 2
- 102100016549 ANPEP Human genes 0.000 claims 1
- 101710028178 ANPEP Proteins 0.000 claims 1
- 208000003950 B-Cell Lymphoma Diseases 0.000 claims 1
- 101700027514 CD14 Proteins 0.000 claims 1
- 102100003268 CD14 Human genes 0.000 claims 1
- 102100005826 CD19 Human genes 0.000 claims 1
- 101700087100 CD19 Proteins 0.000 claims 1
- 101700020617 CD22 Proteins 0.000 claims 1
- 102100000189 CD22 Human genes 0.000 claims 1
- 108060001249 CD24 Proteins 0.000 claims 1
- 102100000197 CD24 Human genes 0.000 claims 1
- 102100019461 CD28 Human genes 0.000 claims 1
- 101700033362 CD28 Proteins 0.000 claims 1
- 101700017647 CD33 Proteins 0.000 claims 1
- 102100016493 CD33 Human genes 0.000 claims 1
- 102100016530 CD37 Human genes 0.000 claims 1
- 101700044364 CD37 Proteins 0.000 claims 1
- 101710040446 CD40 Proteins 0.000 claims 1
- 102100013137 CD40 Human genes 0.000 claims 1
- 108010058905 CD44v6 antigen Proteins 0.000 claims 1
- 101700042459 CFDP1 Proteins 0.000 claims 1
- 102100009368 CR2 Human genes 0.000 claims 1
- 101700020447 CR2 Proteins 0.000 claims 1
- 241000189662 Calla Species 0.000 claims 1
- 101710006782 EIF4G2 Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 101700053597 FCER2 Proteins 0.000 claims 1
- 102100014608 FCER2 Human genes 0.000 claims 1
- 102100015540 FCGR1A Human genes 0.000 claims 1
- 101710003440 FCGR1A Proteins 0.000 claims 1
- 101710044640 FCGR2A Proteins 0.000 claims 1
- 101710044641 FCGR2B Proteins 0.000 claims 1
- 102100015544 FCGR2C Human genes 0.000 claims 1
- 101710044642 FCGR2C Proteins 0.000 claims 1
- 102100015541 FCGR3A Human genes 0.000 claims 1
- 101710044656 FCGR3A Proteins 0.000 claims 1
- 101710044657 FCGR3B Proteins 0.000 claims 1
- 101710026116 Fs(2)Ket Proteins 0.000 claims 1
- 101710011469 GEMIN4 Proteins 0.000 claims 1
- 208000005017 Glioblastoma Diseases 0.000 claims 1
- 101710044247 ITGA2B Proteins 0.000 claims 1
- 102100019332 ITGA2B Human genes 0.000 claims 1
- 108010043496 Immunoglobulin Idiotypes Proteins 0.000 claims 1
- 108090000028 MMP12 Proteins 0.000 claims 1
- 102100000165 MS4A1 Human genes 0.000 claims 1
- 101710010909 MS4A1 Proteins 0.000 claims 1
- 206010025650 Malignant melanoma Diseases 0.000 claims 1
- 102000003729 Neprilysin Human genes 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 101710044433 SAG Proteins 0.000 claims 1
- 231100000617 Superantigen Toxicity 0.000 claims 1
- 206010042971 T-cell lymphoma Diseases 0.000 claims 1
- 102100008904 TFRC Human genes 0.000 claims 1
- 101710036041 TFRC Proteins 0.000 claims 1
- 101710040533 TNFRSF8 Proteins 0.000 claims 1
- 102100009538 TNFRSF8 Human genes 0.000 claims 1
- 101700069487 VCP Proteins 0.000 claims 1
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 1
- 229960002685 biotin Drugs 0.000 claims 1
- 235000020958 biotin Nutrition 0.000 claims 1
- 239000011616 biotin Substances 0.000 claims 1
- 201000008275 breast carcinoma Diseases 0.000 claims 1
- -1 c-erb-B2 Proteins 0.000 claims 1
- 201000011231 colorectal cancer Diseases 0.000 claims 1
- 201000010989 colorectal carcinoma Diseases 0.000 claims 1
- 229920003013 deoxyribonucleic acid Polymers 0.000 claims 1
- 150000002270 gangliosides Chemical class 0.000 claims 1
- 201000011614 malignant glioma Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000001539 ovarian carcinoma Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 210000001519 tissues Anatomy 0.000 claims 1
- 238000000338 in vitro Methods 0.000 abstract 1
Abstract
L'invention concerne des anticorps présentant deux spécificités ou plus, identifiant deux différents antigènes situés sur une cellule tumorale, ainsi que des médicaments et des compositions diagnostiques contenant lesdits anticorps. Les anticorps et les médicaments décrits s'utilisent notamment pour l'identification et l'élimination spécifiques de cellules tumorales in vivo ou in vitro.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE1995131348 DE19531348A1 (de) | 1995-08-25 | 1995-08-25 | Antikörper mit zwei oder mehr Spezifitäten zur selektiven Eliminierung von Zellen in vivo |
| DE19531348.8 | 1995-08-25 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO1997008205A1 WO1997008205A1 (fr) | 1997-03-06 |
| WO1997008205B1 true WO1997008205B1 (fr) | 1997-05-15 |
Family
ID=7770410
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP1996/003734 WO1997008205A1 (fr) | 1995-08-25 | 1996-08-23 | Anticorps presentant deux specificites ou plus pour l'elimination specifique de cellules in vivo |
Country Status (2)
| Country | Link |
|---|---|
| DE (1) | DE19531348A1 (fr) |
| WO (1) | WO1997008205A1 (fr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2753368B1 (fr) | 1996-09-13 | 1999-01-08 | Chauvin Jean Luc | Cage d'osteosynthese expansive |
| BRPI9909860B8 (pt) | 1998-04-21 | 2021-05-25 | Amgen Res Munich Gmbh | polipeptídeo multifuncional de cadeia simples, polinucleotídeo, vetor, célula procariótica, de levedura ou unicelular, composição, usos de polipeptídeo e polinucleotídeo e métodos para preparo do referido polipeptídeo e para identificação de ativadores ou inibidores de ativação ou estimulação das células t |
| DE10034607A1 (de) | 2000-07-20 | 2002-02-07 | Gundram Jung | Multispezifisches Reagenz zur selektiven Stimulierung von Zelloberflächenrezeptoren |
| DE10043437A1 (de) * | 2000-09-04 | 2002-03-28 | Horst Lindhofer | Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites |
| AT413486B (de) * | 2002-07-03 | 2006-03-15 | Igeneon Krebs Immuntherapie | Verwendung eines antikörpers gerichtet gegen lewis-antigene |
| AT500648B1 (de) | 2002-08-12 | 2010-03-15 | Igeneon Krebs Immuntherapie | Set zur behandlung von krebspatienten |
| CA2522586C (fr) | 2003-05-31 | 2017-02-21 | Micromet Ag | Compositions pharmaceutiques comprenant des constructions d'anticorps anti-cd3, anti-cd19 bispecifiques pour le traitement de troubles associes aux lymphocytes b |
| JP5010281B2 (ja) | 2003-05-31 | 2012-08-29 | マイクロメット アクツィエン ゲゼルシャフト | Ｅｐｃａｍに対する二重特異性抗体を含む薬学的組成物 |
| WO2015187937A1 (fr) | 2014-06-04 | 2015-12-10 | Wenzel Spine, Inc. | Dispositif de fusion de corps intervertébral à extension bilatérale |
| MA47458A (fr) | 2017-02-07 | 2019-12-18 | Oblique Therapeutics Ab | Pyridines à substitution hydrocarbylsulfonyle et leur utilisation dans le traitement du cancer |
| US11219531B2 (en) | 2019-04-10 | 2022-01-11 | Wenzel Spine, Inc. | Rotatable intervertebral spacing implant |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4978745A (en) * | 1987-11-23 | 1990-12-18 | Centocor, Inc. | Immunoreactive heterochain antibodies |
| WO1991003493A1 (fr) * | 1989-08-29 | 1991-03-21 | The University Of Southampton | CONJUGUES F(ab)3 ou F(ab)4 bi ou trispécifiques |
| ZA914625B (en) * | 1990-06-22 | 1993-02-24 | Lilly Co Eli | In vivo targeting with bifunctional antibodies |
| DE4028955A1 (de) * | 1990-09-12 | 1992-03-19 | Boehringer Mannheim Gmbh | Monoklonale antikoerper gegen den interleukin 2-rezeptor |
| FR2672291A1 (fr) * | 1991-01-31 | 1992-08-07 | Inst Nat Sante Rech Med | Composition d'anticorps diriges contre le recepteur de l'interleukine-2 humaine ou animale. |
| WO1993002105A1 (fr) * | 1991-07-19 | 1993-02-04 | Hybritech Incorporated | Composes trifonctionnels presentant une specificite contre les cellules resistant a plusieurs medicaments____________________ |
| WO1994024163A2 (fr) * | 1993-04-09 | 1994-10-27 | Chiron Corporation | Molecules bispecifiques de fixation d'antigenes |
-
1995
- 1995-08-25 DE DE1995131348 patent/DE19531348A1/de not_active Withdrawn
-
1996
- 1996-08-23 WO PCT/EP1996/003734 patent/WO1997008205A1/fr active Application Filing
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO1997008205B1 (fr) | Anticorps presentant deux specificites ou plus pour l'elimination specifique de cellules in vivo | |
| Mezzanzanica et al. | Human ovarian carcinoma lysis by cytotoxic T cells targeted by bispecific monoclonal antibodies: analysis of the antibody components | |
| US4978745A (en) | Immunoreactive heterochain antibodies | |
| Cherepakhin et al. | Common clonal origin of chronic lymphocytic leukemia and high-grade lymphoma of Richter's syndrome | |
| Weiner et al. | Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and FcγRIII | |
| AU761387B2 (en) | Bispecific antibodies for retargeting anticancer cytotoxic lymphocytes and hybriomas and monoclonal antibodies therefore | |
| AU605771B2 (en) | Monoclanal antibodies to Fc receptors for immunoglobulin G on human mononuclear phagocytes | |
| MY108519A (en) | Novel antibodies reactive with human carcinomas. | |
| EP0256654A3 (fr) | Immunoglobuline chimère murine-humaine, spécifique pour l' antigène 17-1A associés aux tumeurs | |
| EP0369566A2 (fr) | Anticorps chimériques bifonctionnels | |
| Dorvillius et al. | Targeting of human breast cancer by a bispecific antibody directed against two tumour-associated antigens: ErbB-2 and carcinoembryonic antigen | |
| EP0845998B1 (fr) | Medicaments s'utilisant en immunotherapie et contenant des anticorps identifiant specifiquement l'antigene du mhcii d'un patient a traiter | |
| Thompson et al. | Monoclonal antibodies to human colon and colorectal carcinoma | |
| WO1997007819B1 (fr) | Medicaments s'utilisant en immunotherapie et contenant des anticorps identifiant specifiquement l'antigene du mhcii d'un patient a traiter | |
| Michon et al. | In vitro killing of neuroblastoma cells by neutrophils derived from granulocyte colony-stimulating factor-treated cancer patients using an anti-disialoganglioside/anti-Fc gamma RI bispecific antibody | |
| Hellström et al. | Antibody-mediated killing of human tumor cells by attached effector cells | |
| WO1997008205A1 (fr) | Anticorps presentant deux specificites ou plus pour l'elimination specifique de cellules in vivo | |
| de Gast et al. | Clinical perspectives of bispecific antibodies in cancer | |
| Liao et al. | Immunohistochemical phenotyping of human solid tumors with monoclonal antibodies in devising biotherapeutic strategies | |
| MASUCCI et al. | Effect of Human Blood Mononuclear Cell Populations in Antibody Dependent Cellular Cytotoxicity (ADCC) Using Two Murine (CO 17-1A and Br55-2) and One Chimeric (17-1A) Monoclonal Antibodies Against a Human Colorectal Carcinoma Cell Line (SW948) | |
| Holzer et al. | Superantigen-staphylococal-enterotoxin-A-dependent and antibody-targeted lysis of GD 2-positive neuroblastoma cells | |
| HOMBACH et al. | Grafting T cells with tumor specificity: the chimeric receptor strategy for use in immunotherapy of malignant diseases | |
| EP0213581A2 (fr) | Anticorps monoclonaux contre des glycoprotéines associées aux tumeurs, procédé de préparation et utilisation | |
| Bosslet et al. | Immunological tailoring of monoclonal antibodies for immunotherapy of pancreatic carcinoma | |
| Palumbo et al. | Multiple independent immunoglobulin class‐switch recombinations occurring within the same clone in myeloma |